Table 1.
Mean change from baseline in SF‐36 domains at Weeks 12 and 52
| Domain | Week 12 | Week 52 | |||
|---|---|---|---|---|---|
| PBO/IXE (N = 65) LSM (±SE) | IXE/IXE (N = 74) LSM (±SE) | P‐value | PBO/IXE (N = 65) Mean (±SE) | IXE/IXE (N = 74) Mean (±SE) | |
| Physical functioning | 1.7 (1.8) | 9.7 (1.8) | 0.002 | 10.6 (3.0) | 5.9 (2.1) |
| Role limitations due to physical health | 1.3 (2.0) | 13.5 (2.0) | <0.001 | 10.10 (3.7) | 9.8 (2.8) |
| Bodily pain | 4.1 (2.5) | 20.9 (2.5) | <0.001 | 19.6 (3.7) | 13.9 (3.3) |
| General health perceptions | 2.6 (1.6) | 5.5 (1.6) | 0.215 | 5.2 (2.5) | 3.7 (1.7) |
| Vitality | 2.9 (1.9) | 7.6 (1.9) | 0.081 | 9.4 (2.7) | 4.5 (2.2) |
| Social functioning | 2.9 (2.1) | 14.5 (2.1) | <0.001 | 16.2 (3.3) | 9.5 (3.3) |
| Role limitations due to emotional problems | 4.1 (1.6) | 9.4 (1.6) | 0.02 | 10.1 (3.0) | 4.4 (2.6) |
| Mental health | 3.7 (1.3) | 7.5 (1.3) | 0.041 | 6.5 (2.0) | 5.9 (1.8) |
| PCS | 0.7 (0.8) | 5.2 (0.8) | <0.001 | 4.5 (1.2) | 2.5 (1.1) |
| Mental health component summary (MCS) | 2.2 (0.7) | 4.0 (0.7) | 0.085 | 4.9 (1.3) | 3.6 (0.9) |
Data is change from baseline (mBOCF). The ANCOVA model includes treatment, baseline BSA category, and baseline value.
Abbreviations: BSA, body surface area; IXE, ixekizumab; LSM, least squares mean; mBOCF, modified baseline observation carried forward; MCS, mental health component summary; PBO, placebo; PCS, physical component summary; SE, standard error.